PATENT CLAIM ANALYSIS

Application Number: 15749963
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "235500"]

Abstract:
A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.

Claim (Index 18):
A method of treating and/or preventing of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity, or inhibiting TD02, said method comprising administering a compound according to  claim 1  to a subject in need thereof.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 88.0
- Lexical Diversity: 1.88679
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14619589', '15072534', '14076016', '14765556', '15546251']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7940873054002315
- 35 USC 102 Novelty (BERT): 0.5491938289474645
- Combined Prediction Score: 0.7695979577549548
- Mean Citation Score: 378.49669200000005
- Max Citation Score: 465.86142
- Similarity Product: 265.32655763100394

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test